Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin.
暂无分享,去创建一个
[1] S. K. Kim,et al. Changing epidemiology of nontuberculous mycobacterial lung disease in South Korea , 2012, Scandinavian journal of infectious diseases.
[2] Robert Horsburgh,et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.
[3] R. Wallace,,et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] R. Thomson. Changing Epidemiology of Pulmonary Nontuberculous Mycobacteria Infections , 2010, Emerging infectious diseases.
[5] J. Igual,et al. Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[6] M. Raffeld,et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. , 2008, American journal of respiratory and critical care medicine.
[7] A. Amorim,et al. Non-tuberculous mycobacteria in HIV-negative patients with pulmonary disease in Lisbon, Portugal , 2010, Scandinavian journal of infectious diseases.
[8] F. Drobniewski,et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study , 2013, European Respiratory Journal.
[9] R. Wallace,,et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. , 1995, The Journal of infectious diseases.
[10] A. Niimi,et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. , 1999, American journal of respiratory and critical care medicine.
[11] T. Kanauchi,et al. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. , 2012, American journal of respiratory and critical care medicine.
[12] M. Hargreaves,et al. Isolation of Nontuberculous Mycobacteria (NTM) from Household Water and Shower Aerosols in Patients with Pulmonary Disease Caused by NTM , 2013, Journal of Clinical Microbiology.
[13] R. Wallace,,et al. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. , 2005, American journal of respiratory and critical care medicine.
[14] A. Flahault,et al. Effect of Adding Clofazimine to Combined Clarithromycin-Ethambutol Therapy for Mycobacterium avium Complex Septicemia in AIDS Patients , 1999, European Journal of Clinical Microbiology and Infectious Diseases.
[15] R. Wallace,,et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. , 2002, The Journal of infectious diseases.
[16] R. Chaisson,et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic: Mycobacterium avium complex disease in patients with HIV infection , 1997, AIDS.
[17] K. Winthrop,et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. , 2010, American journal of respiratory and critical care medicine.
[18] R. Wallace,,et al. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. , 1990, The American review of respiratory disease.
[19] Mary Ann Blosky,et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. , 2010, American journal of respiratory and critical care medicine.
[20] T. Marras,et al. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003 , 2007, Thorax.
[21] K. Togashi,et al. High-resolution computed tomography and health-related quality of life in Mycobacterium avium complex disease. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[22] S. Field,et al. Mycobacterium avium complex pulmonary disease in patients without HIV infection. , 2004, Chest.
[23] R. Wallace,,et al. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] John D. Mitchell,et al. Anatomic lung resection for nontuberculous mycobacterial disease. , 2008, The Annals of thoracic surgery.
[25] Mikio Oka,et al. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. , 2007, Respiratory medicine.
[26] C. Ki,et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. , 2015, American journal of respiratory and critical care medicine.
[27] S. Field,et al. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. , 2003, Chest.
[28] Yoshihiro Kobashi,et al. The Microbiological and Clinical Effects of Combined Therapy according to Guidelines on the Treatment of Pulmonary Mycobacterium avium Complex Disease in Japan – Including a Follow-Up Study , 2006, Respiration.
[29] R. Wallace,,et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. , 1996, American journal of respiratory and critical care medicine.
[30] J. Falkinham. Ecology of Nontuberculous Mycobacteria—Where Do Human Infections Come from? , 2013, Seminars in Respiratory and Critical Care Medicine.
[31] C. Daley,et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. , 2012, American journal of respiratory and critical care medicine.
[32] T. Marras,et al. Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. , 2011, Respiratory medicine.
[33] R. Wallace,,et al. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. , 1998, American journal of respiratory and critical care medicine.
[34] Tanya S. Glaser,et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. , 2014, Annals of the American Thoracic Society.
[35] R. Wallace,,et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. , 2014, Chest.
[36] J. Falkinham. Nontuberculous Mycobacteria from Household Plumbing of Patients with Nontuberculous Mycobacteria Disease , 2011, Emerging infectious diseases.